The Atherosclerosis drugs in development market research report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Atherosclerosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued products.

GlobalData tracks 113 drugs in development for Atherosclerosis by 97 companies/universities/institutes. The top development phase for Atherosclerosis is preclinical with 70 drugs in that stage. The Atherosclerosis pipeline has 89 drugs in development by companies and 24 by universities/ institutes. Some of the companies in the Atherosclerosis pipeline products market are: Verve Therapeutics, Vasocure Therapeutics and Eli Lilly and Co.

The key targets in the Atherosclerosis pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), Apolipoprotein A (APOA or LPA), and Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3).

The key mechanisms of action in the Atherosclerosis pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with ten drugs in Phase III. The Atherosclerosis pipeline products include seven routes of administration with the top ROA being Oral and 17 key molecule types in the Atherosclerosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Atherosclerosis overview

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive buildup of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina); pain in the leg, arm, and anywhere else that an artery is blocked; shortness of breath; fatigue; confusion (if the blockage affects circulation to the brain); and muscle weakness in the legs from lack of circulation.

For a complete picture of Atherosclerosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.